ROS1 and neoplasm: We hypothesize that cabozantinib’s enhanced efficacy may derive from its multi-targeted mechanism: direct inhibition of ROS1 L2086F coupled with concurrent suppression of potential bypass signaling pathways mediated by MET and rat sarcoma-mitogen-activated protein kinase,[6] This comprehensive blockade of tumor escape routes may account for its superior and more durable clinical benefit compared to single-target inhibitors.